On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.

On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.